TROPION-Lung01 Results Indicate PFS Benefit with Datopotamab Deruxtecan over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and a Question

This commentary aims to point out how the results of the TROPION-LUNG01 study stress the "positive aspects" of the results, specifically the increase in PFS, but hardly mention the potential harm to patients with squamous histology and lack information on binary data (progression-free / progression, alive/death) as per CONSORT guidelines. Here, we also remark on the need for adherence to CONSORT guidelines to inform on the absolute and relative risks of Randomized Controlled Trials (RCT). We emphasize the need for further research to develop a framework for how oncologists might explain the differences between PFS and OS in simple terms for a lay audience to create a more thoughtful decision for patients to embark on any cancer treatment.